The goal of the Mayo SPORE In Brain Cancer Developmental Research Program (DRP) is to support innovative and scientifically sound projects that investigate questions pertaining to some aspect of translational research in malignant gliomas and other primary brain tumors. The DRP will provide two one year awards of $50,000 each. Dr. Robert B. Jenkins, overall Co-PI of the SPORE, will direct the program. The premise of this program is that support of developmental research projects will result in the generation of new hypotheses that will be tested within SPORE-sponsored projects or through peer-reviewed external grant support. The long-term goal of the program Is to translate the findings generated by developmental grants into effective interventions in patients with, and persons at risk for, primary brain tumors. An equally important goal is the attraction of new Investigators and their expertise to the challenges of brain cancer research. The DRP objectives are to: (1) stimulate Innovative and translationally-relevant laboratory, population science and clinical studies in primary brain tumors;(2) foster extensive collaboration between basic science, population science and clinical disciplines to advance brain tumor translational research, and (3) encourage investigators in related fields to apply their expertise to translational research in brain tumors. The Program will be administered through the Administrative Core of the SPORE. One-page outlines of two potential research projects are included to demonstrate the depth and breadth of ongoing research that can be eligible for funding through the SPORE Developmental Research Program. These two potential projects represent under-developed areas within glioma research.

Public Health Relevance

The Mayo SPORE in Brain Cancer Developmental Research Program was established to fund early phase research that take maximum advantage of SPORE resources to generate feasibility data for projects that have the highest translational potential. In so doing the DRP will develop scientists who will advance and significantly impact the nation's brain tumor agenda.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA108961-09
Application #
8729261
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
9
Fiscal Year
2014
Total Cost
$70,483
Indirect Cost
$25,201
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Hardcastle, Jayson; Mills, Lisa; Malo, Courtney S et al. (2017) Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment. Neuro Oncol 19:493-502
Robinson, Steven; Galanis, Evanthia (2017) Potential and clinical translation of oncolytic measles viruses. Expert Opin Biol Ther 17:353-363
Kurokawa, C; Geekiyanage, H; Allen, C et al. (2017) Alisertib demonstrates significant antitumor activity in bevacizumab resistant, patient derived orthotopic models of glioblastoma. J Neurooncol 131:41-48
Kizilbash, Sani H; Gupta, Shiv K; Chang, Kenneth et al. (2017) Restricted Delivery of Talazoparib Across the Blood-Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 16:2735-2746
Melin, Beatrice S; Barnholtz-Sloan, Jill S; Wrensch, Margaret R et al. (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789-794
Yin, Xueqian; Kang, Jeong-Han; Andrianifahanana, Mahefatiana et al. (2017) Basolateral delivery of the type I transforming growth factor beta receptor is mediated by a dominant-acting cytoplasmic motif. Mol Biol Cell 28:2701-2711
Msaouel, Pavlos; Opyrchal, Mateusz; Dispenzieri, Angela et al. (2017) Clinical Trials with Oncolytic Measles Virus: Current Status and Future Prospects. Curr Cancer Drug Targets :
Heim, Joel B; Squirewell, Edwin J; Neu, Ancilla et al. (2017) Myosin-1E interacts with FAK proline-rich region 1 to induce fibronectin-type matrix. Proc Natl Acad Sci U S A 114:3933-3938
Tivnan, Amanda; Heilinger, Tatjana; Ramsey, Joanne M et al. (2017) Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. Oncotarget 8:16605-16620
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016

Showing the most recent 10 out of 243 publications